nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.199	0.428	CbGbCtD
Dasatinib—CYP1A1—Riluzole—amyotrophic lateral sclerosis	0.184	0.395	CbGbCtD
Dasatinib—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.082	0.177	CbGbCtD
Dasatinib—Cor pulmonale—Riluzole—amyotrophic lateral sclerosis	0.0256	0.133	CcSEcCtD
Dasatinib—Congestive cardiomyopathy—Riluzole—amyotrophic lateral sclerosis	0.0147	0.0761	CcSEcCtD
Dasatinib—Subdural haematoma—Riluzole—amyotrophic lateral sclerosis	0.00737	0.0381	CcSEcCtD
Dasatinib—Subarachnoid haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00708	0.0366	CcSEcCtD
Dasatinib—Uterine haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00442	0.0228	CcSEcCtD
Dasatinib—VIIth nerve paralysis—Riluzole—amyotrophic lateral sclerosis	0.00377	0.0195	CcSEcCtD
Dasatinib—Pericarditis—Riluzole—amyotrophic lateral sclerosis	0.00357	0.0185	CcSEcCtD
Dasatinib—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00279	0.0144	CcSEcCtD
Dasatinib—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00272	0.0141	CcSEcCtD
Dasatinib—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.00269	0.0139	CcSEcCtD
Dasatinib—Generalised oedema—Riluzole—amyotrophic lateral sclerosis	0.0026	0.0134	CcSEcCtD
Dasatinib—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00254	0.0131	CcSEcCtD
Dasatinib—Embolism—Riluzole—amyotrophic lateral sclerosis	0.00241	0.0124	CcSEcCtD
Dasatinib—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00231	0.0119	CcSEcCtD
Dasatinib—Blood creatine phosphokinase increased—Riluzole—amyotrophic lateral sclerosis	0.00224	0.0116	CcSEcCtD
Dasatinib—Ileus—Riluzole—amyotrophic lateral sclerosis	0.00218	0.0113	CcSEcCtD
Dasatinib—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00218	0.0113	CcSEcCtD
Dasatinib—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00218	0.0113	CcSEcCtD
Dasatinib—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.00209	0.0108	CcSEcCtD
Dasatinib—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00202	0.0104	CcSEcCtD
Dasatinib—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00198	0.0103	CcSEcCtD
Dasatinib—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00188	0.0097	CcSEcCtD
Dasatinib—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00172	0.0089	CcSEcCtD
Dasatinib—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00844	CcSEcCtD
Dasatinib—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00798	CcSEcCtD
Dasatinib—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00798	CcSEcCtD
Dasatinib—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00147	0.00758	CcSEcCtD
Dasatinib—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00722	CcSEcCtD
Dasatinib—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00722	CcSEcCtD
Dasatinib—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00138	0.00711	CcSEcCtD
Dasatinib—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00693	CcSEcCtD
Dasatinib—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00128	0.0066	CcSEcCtD
Dasatinib—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00645	CcSEcCtD
Dasatinib—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00124	0.00639	CcSEcCtD
Dasatinib—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00625	CcSEcCtD
Dasatinib—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00617	CcSEcCtD
Dasatinib—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00612	CcSEcCtD
Dasatinib—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00594	CcSEcCtD
Dasatinib—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00112	0.0058	CcSEcCtD
Dasatinib—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00111	0.00575	CcSEcCtD
Dasatinib—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.0011	0.0057	CcSEcCtD
Dasatinib—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00559	CcSEcCtD
Dasatinib—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00527	CcSEcCtD
Dasatinib—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00524	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00522	CcSEcCtD
Dasatinib—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.000992	0.00513	CcSEcCtD
Dasatinib—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.000989	0.00511	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.000989	0.00511	CcSEcCtD
Dasatinib—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.000976	0.00504	CcSEcCtD
Dasatinib—Asthma—Riluzole—amyotrophic lateral sclerosis	0.000969	0.00501	CcSEcCtD
Dasatinib—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.000969	0.00501	CcSEcCtD
Dasatinib—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00095	0.00491	CcSEcCtD
Dasatinib—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.000944	0.00488	CcSEcCtD
Dasatinib—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00092	0.00476	CcSEcCtD
Dasatinib—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.000906	0.00468	CcSEcCtD
Dasatinib—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.000895	0.00463	CcSEcCtD
Dasatinib—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.000885	0.00457	CcSEcCtD
Dasatinib—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.000882	0.00456	CcSEcCtD
Dasatinib—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.000877	0.00453	CcSEcCtD
Dasatinib—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.000869	0.00449	CcSEcCtD
Dasatinib—Infestation—Riluzole—amyotrophic lateral sclerosis	0.000864	0.00447	CcSEcCtD
Dasatinib—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.000864	0.00447	CcSEcCtD
Dasatinib—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.000852	0.0044	CcSEcCtD
Dasatinib—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.000847	0.00438	CcSEcCtD
Dasatinib—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.000847	0.00438	CcSEcCtD
Dasatinib—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.000842	0.00435	CcSEcCtD
Dasatinib—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.000824	0.00426	CcSEcCtD
Dasatinib—KIT—hindbrain—amyotrophic lateral sclerosis	0.00082	0.00558	CbGeAlD
Dasatinib—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.000817	0.00422	CcSEcCtD
Dasatinib—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000815	0.00421	CcSEcCtD
Dasatinib—SIK2—nervous system—amyotrophic lateral sclerosis	0.000794	0.0054	CbGeAlD
Dasatinib—MAPK14—embryo—amyotrophic lateral sclerosis	0.000781	0.00531	CbGeAlD
Dasatinib—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00078	0.00403	CcSEcCtD
Dasatinib—FGR—embryo—amyotrophic lateral sclerosis	0.000778	0.00529	CbGeAlD
Dasatinib—EPHA4—brainstem—amyotrophic lateral sclerosis	0.000776	0.00527	CbGeAlD
Dasatinib—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000776	0.00401	CcSEcCtD
Dasatinib—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000776	0.00401	CcSEcCtD
Dasatinib—PKMYT1—nervous system—amyotrophic lateral sclerosis	0.000774	0.00526	CbGeAlD
Dasatinib—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000766	0.00396	CcSEcCtD
Dasatinib—SIK2—central nervous system—amyotrophic lateral sclerosis	0.000765	0.0052	CbGeAlD
Dasatinib—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.000764	0.00395	CcSEcCtD
Dasatinib—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000762	0.00394	CcSEcCtD
Dasatinib—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00076	0.00393	CcSEcCtD
Dasatinib—PKMYT1—central nervous system—amyotrophic lateral sclerosis	0.000745	0.00507	CbGeAlD
Dasatinib—EPHB2—nervous system—amyotrophic lateral sclerosis	0.000738	0.00502	CbGeAlD
Dasatinib—JAK2—embryo—amyotrophic lateral sclerosis	0.000735	0.005	CbGeAlD
Dasatinib—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000734	0.00379	CcSEcCtD
Dasatinib—EPHA5—medulla oblongata—amyotrophic lateral sclerosis	0.000729	0.00495	CbGeAlD
Dasatinib—PKMYT1—cerebellum—amyotrophic lateral sclerosis	0.000728	0.00495	CbGeAlD
Dasatinib—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000725	0.00375	CcSEcCtD
Dasatinib—FYN—embryo—amyotrophic lateral sclerosis	0.000725	0.00493	CbGeAlD
Dasatinib—SRMS—nervous system—amyotrophic lateral sclerosis	0.000723	0.00491	CbGeAlD
Dasatinib—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00072	0.00372	CcSEcCtD
Dasatinib—MAPK14—brainstem—amyotrophic lateral sclerosis	0.000715	0.00486	CbGeAlD
Dasatinib—ABL1—hindbrain—amyotrophic lateral sclerosis	0.000714	0.00485	CbGeAlD
Dasatinib—EPHB2—central nervous system—amyotrophic lateral sclerosis	0.000711	0.00483	CbGeAlD
Dasatinib—BTK—medulla oblongata—amyotrophic lateral sclerosis	0.00071	0.00483	CbGeAlD
Dasatinib—EPHA8—nervous system—amyotrophic lateral sclerosis	0.000708	0.00481	CbGeAlD
Dasatinib—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000704	0.00364	CcSEcCtD
Dasatinib—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000701	0.00362	CcSEcCtD
Dasatinib—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000699	0.00361	CcSEcCtD
Dasatinib—Chills—Riluzole—amyotrophic lateral sclerosis	0.000696	0.0036	CcSEcCtD
Dasatinib—SRMS—central nervous system—amyotrophic lateral sclerosis	0.000696	0.00473	CbGeAlD
Dasatinib—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000693	0.00358	CcSEcCtD
Dasatinib—EPHB1—brain—amyotrophic lateral sclerosis	0.000687	0.00467	CbGeAlD
Dasatinib—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000686	0.00354	CcSEcCtD
Dasatinib—EPHA8—central nervous system—amyotrophic lateral sclerosis	0.000682	0.00463	CbGeAlD
Dasatinib—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00068	0.00351	CcSEcCtD
Dasatinib—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000675	0.00349	CcSEcCtD
Dasatinib—STAT5B—nervous system—amyotrophic lateral sclerosis	0.000669	0.00455	CbGeAlD
Dasatinib—EPHA8—cerebellum—amyotrophic lateral sclerosis	0.000666	0.00453	CbGeAlD
Dasatinib—FYN—brainstem—amyotrophic lateral sclerosis	0.000664	0.00452	CbGeAlD
Dasatinib—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000661	0.00342	CcSEcCtD
Dasatinib—TESK1—medulla oblongata—amyotrophic lateral sclerosis	0.000658	0.00447	CbGeAlD
Dasatinib—EPHA5—spinal cord—amyotrophic lateral sclerosis	0.00065	0.00442	CbGeAlD
Dasatinib—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000649	0.00336	CcSEcCtD
Dasatinib—STK36—medulla oblongata—amyotrophic lateral sclerosis	0.000648	0.0044	CbGeAlD
Dasatinib—STAT5B—central nervous system—amyotrophic lateral sclerosis	0.000644	0.00438	CbGeAlD
Dasatinib—PDGFRA—embryo—amyotrophic lateral sclerosis	0.000642	0.00436	CbGeAlD
Dasatinib—BTK—spinal cord—amyotrophic lateral sclerosis	0.000634	0.00431	CbGeAlD
Dasatinib—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000633	0.00327	CcSEcCtD
Dasatinib—STAT5B—cerebellum—amyotrophic lateral sclerosis	0.00063	0.00428	CbGeAlD
Dasatinib—SRC—embryo—amyotrophic lateral sclerosis	0.000629	0.00428	CbGeAlD
Dasatinib—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000627	0.00324	CcSEcCtD
Dasatinib—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000624	0.00323	CcSEcCtD
Dasatinib—EPHA3—nervous system—amyotrophic lateral sclerosis	0.000619	0.00421	CbGeAlD
Dasatinib—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000609	0.00315	CcSEcCtD
Dasatinib—SIK2—brain—amyotrophic lateral sclerosis	0.000607	0.00413	CbGeAlD
Dasatinib—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000607	0.00314	CcSEcCtD
Dasatinib—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000606	0.00313	CcSEcCtD
Dasatinib—CSK—medulla oblongata—amyotrophic lateral sclerosis	0.000603	0.0041	CbGeAlD
Dasatinib—SIK3—nervous system—amyotrophic lateral sclerosis	0.000602	0.00409	CbGeAlD
Dasatinib—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.000597	0.00308	CcSEcCtD
Dasatinib—EPHA3—central nervous system—amyotrophic lateral sclerosis	0.000596	0.00405	CbGeAlD
Dasatinib—HCK—medulla oblongata—amyotrophic lateral sclerosis	0.000595	0.00405	CbGeAlD
Dasatinib—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000594	0.00307	CcSEcCtD
Dasatinib—PKMYT1—brain—amyotrophic lateral sclerosis	0.000592	0.00402	CbGeAlD
Dasatinib—Cough—Riluzole—amyotrophic lateral sclerosis	0.000589	0.00305	CcSEcCtD
Dasatinib—TESK1—spinal cord—amyotrophic lateral sclerosis	0.000587	0.00399	CbGeAlD
Dasatinib—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000585	0.00302	CcSEcCtD
Dasatinib—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000583	0.00301	CcSEcCtD
Dasatinib—SIK3—central nervous system—amyotrophic lateral sclerosis	0.000579	0.00394	CbGeAlD
Dasatinib—EPHB3—spinal cord—amyotrophic lateral sclerosis	0.000578	0.00393	CbGeAlD
Dasatinib—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000575	0.00297	CcSEcCtD
Dasatinib—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000575	0.00297	CcSEcCtD
Dasatinib—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000575	0.00297	CcSEcCtD
Dasatinib—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000573	0.00296	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000571	0.00295	CcSEcCtD
Dasatinib—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000568	0.00294	CcSEcCtD
Dasatinib—SIK3—cerebellum—amyotrophic lateral sclerosis	0.000566	0.00385	CbGeAlD
Dasatinib—CSF1R—embryo—amyotrophic lateral sclerosis	0.000565	0.00384	CbGeAlD
Dasatinib—EPHB2—brain—amyotrophic lateral sclerosis	0.000564	0.00384	CbGeAlD
Dasatinib—RIPK2—medulla oblongata—amyotrophic lateral sclerosis	0.00056	0.0038	CbGeAlD
Dasatinib—ZAK—nervous system—amyotrophic lateral sclerosis	0.00056	0.0038	CbGeAlD
Dasatinib—LIMK2—spinal cord—amyotrophic lateral sclerosis	0.000558	0.0038	CbGeAlD
Dasatinib—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000556	0.00287	CcSEcCtD
Dasatinib—SRMS—brain—amyotrophic lateral sclerosis	0.000552	0.00375	CbGeAlD
Dasatinib—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000551	0.00285	CcSEcCtD
Dasatinib—EPHA5—nervous system—amyotrophic lateral sclerosis	0.000548	0.00372	CbGeAlD
Dasatinib—Infection—Riluzole—amyotrophic lateral sclerosis	0.000548	0.00283	CcSEcCtD
Dasatinib—SIK1—medulla oblongata—amyotrophic lateral sclerosis	0.000547	0.00372	CbGeAlD
Dasatinib—LYN—nervous system—amyotrophic lateral sclerosis	0.000545	0.0037	CbGeAlD
Dasatinib—Shock—Riluzole—amyotrophic lateral sclerosis	0.000542	0.0028	CcSEcCtD
Dasatinib—EPHA4—medulla oblongata—amyotrophic lateral sclerosis	0.000541	0.00368	CbGeAlD
Dasatinib—EPHA8—brain—amyotrophic lateral sclerosis	0.000541	0.00368	CbGeAlD
Dasatinib—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000541	0.00279	CcSEcCtD
Dasatinib—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00054	0.00279	CcSEcCtD
Dasatinib—ZAK—central nervous system—amyotrophic lateral sclerosis	0.000539	0.00366	CbGeAlD
Dasatinib—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000538	0.00278	CcSEcCtD
Dasatinib—CSK—spinal cord—amyotrophic lateral sclerosis	0.000538	0.00366	CbGeAlD
Dasatinib—BMPR1B—nervous system—amyotrophic lateral sclerosis	0.000536	0.00365	CbGeAlD
Dasatinib—MAP3K19—nervous system—amyotrophic lateral sclerosis	0.000536	0.00365	CbGeAlD
Dasatinib—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000535	0.00277	CcSEcCtD
Dasatinib—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000533	0.00275	CcSEcCtD
Dasatinib—HCK—spinal cord—amyotrophic lateral sclerosis	0.000531	0.00361	CbGeAlD
Dasatinib—MAP2K5—brainstem—amyotrophic lateral sclerosis	0.000531	0.00361	CbGeAlD
Dasatinib—EPHA5—central nervous system—amyotrophic lateral sclerosis	0.000527	0.00358	CbGeAlD
Dasatinib—ZAK—cerebellum—amyotrophic lateral sclerosis	0.000527	0.00358	CbGeAlD
Dasatinib—TNK2—nervous system—amyotrophic lateral sclerosis	0.000526	0.00358	CbGeAlD
Dasatinib—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000525	0.00271	CcSEcCtD
Dasatinib—LYN—central nervous system—amyotrophic lateral sclerosis	0.000524	0.00357	CbGeAlD
Dasatinib—MAP3K19—central nervous system—amyotrophic lateral sclerosis	0.000516	0.00351	CbGeAlD
Dasatinib—BMPR1B—central nervous system—amyotrophic lateral sclerosis	0.000516	0.00351	CbGeAlD
Dasatinib—EPHA5—cerebellum—amyotrophic lateral sclerosis	0.000515	0.0035	CbGeAlD
Dasatinib—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000515	0.00266	CcSEcCtD
Dasatinib—KIT—embryo—amyotrophic lateral sclerosis	0.000513	0.00349	CbGeAlD
Dasatinib—STAT5B—brain—amyotrophic lateral sclerosis	0.000512	0.00348	CbGeAlD
Dasatinib—TNK2—central nervous system—amyotrophic lateral sclerosis	0.000507	0.00344	CbGeAlD
Dasatinib—BMPR1B—cerebellum—amyotrophic lateral sclerosis	0.000505	0.00343	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000502	0.00259	CcSEcCtD
Dasatinib—PDGFRB—embryo—amyotrophic lateral sclerosis	0.000501	0.00341	CbGeAlD
Dasatinib—RIPK2—spinal cord—amyotrophic lateral sclerosis	0.000499	0.00339	CbGeAlD
Dasatinib—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000498	0.00258	CcSEcCtD
Dasatinib—TNK2—cerebellum—amyotrophic lateral sclerosis	0.000495	0.00337	CbGeAlD
Dasatinib—TESK1—nervous system—amyotrophic lateral sclerosis	0.000495	0.00336	CbGeAlD
Dasatinib—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000491	0.00254	CcSEcCtD
Dasatinib—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00049	0.00253	CcSEcCtD
Dasatinib—SIK1—spinal cord—amyotrophic lateral sclerosis	0.000487	0.00331	CbGeAlD
Dasatinib—EPHB3—nervous system—amyotrophic lateral sclerosis	0.000487	0.00331	CbGeAlD
Dasatinib—STK36—nervous system—amyotrophic lateral sclerosis	0.000487	0.00331	CbGeAlD
Dasatinib—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000485	0.00251	CcSEcCtD
Dasatinib—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000479	0.00248	CcSEcCtD
Dasatinib—ERBB3—spinal cord—amyotrophic lateral sclerosis	0.000478	0.00325	CbGeAlD
Dasatinib—TESK1—central nervous system—amyotrophic lateral sclerosis	0.000476	0.00324	CbGeAlD
Dasatinib—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000476	0.00246	CcSEcCtD
Dasatinib—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000475	0.00246	CcSEcCtD
Dasatinib—EPHB4—medulla oblongata—amyotrophic lateral sclerosis	0.000473	0.00321	CbGeAlD
Dasatinib—EPHA3—brain—amyotrophic lateral sclerosis	0.000473	0.00321	CbGeAlD
Dasatinib—Pain—Riluzole—amyotrophic lateral sclerosis	0.000471	0.00244	CcSEcCtD
Dasatinib—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000471	0.00244	CcSEcCtD
Dasatinib—LIMK2—nervous system—amyotrophic lateral sclerosis	0.000471	0.0032	CbGeAlD
Dasatinib—KIT—brainstem—amyotrophic lateral sclerosis	0.00047	0.0032	CbGeAlD
Dasatinib—JAK2—medulla oblongata—amyotrophic lateral sclerosis	0.00047	0.00319	CbGeAlD
Dasatinib—STK36—central nervous system—amyotrophic lateral sclerosis	0.000469	0.00319	CbGeAlD
Dasatinib—EPHB3—central nervous system—amyotrophic lateral sclerosis	0.000469	0.00319	CbGeAlD
Dasatinib—TESK1—cerebellum—amyotrophic lateral sclerosis	0.000465	0.00316	CbGeAlD
Dasatinib—FYN—medulla oblongata—amyotrophic lateral sclerosis	0.000463	0.00315	CbGeAlD
Dasatinib—SIK3—brain—amyotrophic lateral sclerosis	0.00046	0.00313	CbGeAlD
Dasatinib—STK36—cerebellum—amyotrophic lateral sclerosis	0.000458	0.00311	CbGeAlD
Dasatinib—EPHB3—cerebellum—amyotrophic lateral sclerosis	0.000458	0.00311	CbGeAlD
Dasatinib—STK35—nervous system—amyotrophic lateral sclerosis	0.000456	0.0031	CbGeAlD
Dasatinib—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000454	0.00235	CcSEcCtD
Dasatinib—CSK—nervous system—amyotrophic lateral sclerosis	0.000453	0.00308	CbGeAlD
Dasatinib—LIMK2—central nervous system—amyotrophic lateral sclerosis	0.000453	0.00308	CbGeAlD
Dasatinib—MAP3K3—medulla oblongata—amyotrophic lateral sclerosis	0.000453	0.00308	CbGeAlD
Dasatinib—MAP4K5—medulla oblongata—amyotrophic lateral sclerosis	0.000453	0.00308	CbGeAlD
Dasatinib—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000451	0.00233	CcSEcCtD
Dasatinib—HCK—nervous system—amyotrophic lateral sclerosis	0.000447	0.00304	CbGeAlD
Dasatinib—ABL1—embryo—amyotrophic lateral sclerosis	0.000447	0.00304	CbGeAlD
Dasatinib—MAPK14—spinal cord—amyotrophic lateral sclerosis	0.000445	0.00302	CbGeAlD
Dasatinib—LIMK2—cerebellum—amyotrophic lateral sclerosis	0.000443	0.00301	CbGeAlD
Dasatinib—STK35—central nervous system—amyotrophic lateral sclerosis	0.000439	0.00299	CbGeAlD
Dasatinib—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000438	0.00226	CcSEcCtD
Dasatinib—CSK—central nervous system—amyotrophic lateral sclerosis	0.000436	0.00297	CbGeAlD
Dasatinib—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000436	0.00225	CcSEcCtD
Dasatinib—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000436	0.00225	CcSEcCtD
Dasatinib—EPHB6—medulla oblongata—amyotrophic lateral sclerosis	0.000433	0.00294	CbGeAlD
Dasatinib—HCK—central nervous system—amyotrophic lateral sclerosis	0.000431	0.00293	CbGeAlD
Dasatinib—STK35—cerebellum—amyotrophic lateral sclerosis	0.000429	0.00292	CbGeAlD
Dasatinib—ZAK—brain—amyotrophic lateral sclerosis	0.000428	0.00291	CbGeAlD
Dasatinib—CSK—cerebellum—amyotrophic lateral sclerosis	0.000426	0.0029	CbGeAlD
Dasatinib—EPHB4—spinal cord—amyotrophic lateral sclerosis	0.000422	0.00287	CbGeAlD
Dasatinib—JAK2—spinal cord—amyotrophic lateral sclerosis	0.000419	0.00285	CbGeAlD
Dasatinib—EPHA5—brain—amyotrophic lateral sclerosis	0.000419	0.00285	CbGeAlD
Dasatinib—ABL2—cerebellum—amyotrophic lateral sclerosis	0.000418	0.00284	CbGeAlD
Dasatinib—YES1—medulla oblongata—amyotrophic lateral sclerosis	0.000418	0.00284	CbGeAlD
Dasatinib—LYN—brain—amyotrophic lateral sclerosis	0.000416	0.00283	CbGeAlD
Dasatinib—FYN—spinal cord—amyotrophic lateral sclerosis	0.000413	0.00281	CbGeAlD
Dasatinib—SIK1—nervous system—amyotrophic lateral sclerosis	0.000411	0.00279	CbGeAlD
Dasatinib—BMPR1B—brain—amyotrophic lateral sclerosis	0.00041	0.00279	CbGeAlD
Dasatinib—MAP3K19—brain—amyotrophic lateral sclerosis	0.00041	0.00279	CbGeAlD
Dasatinib—ABL1—brainstem—amyotrophic lateral sclerosis	0.000409	0.00278	CbGeAlD
Dasatinib—BTK—brain—amyotrophic lateral sclerosis	0.000408	0.00277	CbGeAlD
Dasatinib—EPHA4—nervous system—amyotrophic lateral sclerosis	0.000407	0.00276	CbGeAlD
Dasatinib—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000406	0.0021	CcSEcCtD
Dasatinib—MAP4K5—spinal cord—amyotrophic lateral sclerosis	0.000404	0.00274	CbGeAlD
Dasatinib—MAP3K3—spinal cord—amyotrophic lateral sclerosis	0.000404	0.00274	CbGeAlD
Dasatinib—ERBB3—nervous system—amyotrophic lateral sclerosis	0.000403	0.00274	CbGeAlD
Dasatinib—TNK2—brain—amyotrophic lateral sclerosis	0.000402	0.00273	CbGeAlD
Dasatinib—MAP3K2—nervous system—amyotrophic lateral sclerosis	0.000399	0.00271	CbGeAlD
Dasatinib—RIPK2—cerebellum—amyotrophic lateral sclerosis	0.000396	0.00269	CbGeAlD
Dasatinib—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000395	0.00204	CcSEcCtD
Dasatinib—SIK1—central nervous system—amyotrophic lateral sclerosis	0.000395	0.00269	CbGeAlD
Dasatinib—EPHA4—central nervous system—amyotrophic lateral sclerosis	0.000391	0.00266	CbGeAlD
Dasatinib—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00039	0.00202	CcSEcCtD
Dasatinib—ERBB3—central nervous system—amyotrophic lateral sclerosis	0.000388	0.00263	CbGeAlD
Dasatinib—SIK1—cerebellum—amyotrophic lateral sclerosis	0.000386	0.00263	CbGeAlD
Dasatinib—EPHB6—spinal cord—amyotrophic lateral sclerosis	0.000386	0.00262	CbGeAlD
Dasatinib—MAP3K2—central nervous system—amyotrophic lateral sclerosis	0.000384	0.00261	CbGeAlD
Dasatinib—EPHA4—cerebellum—amyotrophic lateral sclerosis	0.000383	0.0026	CbGeAlD
Dasatinib—ERBB3—cerebellum—amyotrophic lateral sclerosis	0.000379	0.00258	CbGeAlD
Dasatinib—TESK1—brain—amyotrophic lateral sclerosis	0.000378	0.00257	CbGeAlD
Dasatinib—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000377	0.00195	CcSEcCtD
Dasatinib—MAP3K2—cerebellum—amyotrophic lateral sclerosis	0.000375	0.00255	CbGeAlD
Dasatinib—MAPK14—nervous system—amyotrophic lateral sclerosis	0.000375	0.00255	CbGeAlD
Dasatinib—FGR—nervous system—amyotrophic lateral sclerosis	0.000373	0.00254	CbGeAlD
Dasatinib—YES1—spinal cord—amyotrophic lateral sclerosis	0.000373	0.00253	CbGeAlD
Dasatinib—EPHB3—brain—amyotrophic lateral sclerosis	0.000372	0.00253	CbGeAlD
Dasatinib—STK36—brain—amyotrophic lateral sclerosis	0.000372	0.00253	CbGeAlD
Dasatinib—MAP2K5—medulla oblongata—amyotrophic lateral sclerosis	0.00037	0.00251	CbGeAlD
Dasatinib—PDGFRA—spinal cord—amyotrophic lateral sclerosis	0.000366	0.00249	CbGeAlD
Dasatinib—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000364	0.00188	CcSEcCtD
Dasatinib—CSF1R—medulla oblongata—amyotrophic lateral sclerosis	0.000361	0.00245	CbGeAlD
Dasatinib—MAPK14—central nervous system—amyotrophic lateral sclerosis	0.000361	0.00245	CbGeAlD
Dasatinib—FMO3—nervous system—amyotrophic lateral sclerosis	0.000361	0.00245	CbGeAlD
Dasatinib—LIMK2—brain—amyotrophic lateral sclerosis	0.00036	0.00245	CbGeAlD
Dasatinib—FGR—central nervous system—amyotrophic lateral sclerosis	0.000359	0.00244	CbGeAlD
Dasatinib—SRC—spinal cord—amyotrophic lateral sclerosis	0.000359	0.00244	CbGeAlD
Dasatinib—JAK2—nervous system—amyotrophic lateral sclerosis	0.000353	0.0024	CbGeAlD
Dasatinib—MAPK14—cerebellum—amyotrophic lateral sclerosis	0.000353	0.0024	CbGeAlD
Dasatinib—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00035	0.00181	CcSEcCtD
Dasatinib—STK35—brain—amyotrophic lateral sclerosis	0.000349	0.00237	CbGeAlD
Dasatinib—EPHA2—nervous system—amyotrophic lateral sclerosis	0.000349	0.00237	CbGeAlD
Dasatinib—FYN—nervous system—amyotrophic lateral sclerosis	0.000348	0.00237	CbGeAlD
Dasatinib—Rash—Riluzole—amyotrophic lateral sclerosis	0.000348	0.0018	CcSEcCtD
Dasatinib—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000347	0.00179	CcSEcCtD
Dasatinib—FMO3—central nervous system—amyotrophic lateral sclerosis	0.000347	0.00236	CbGeAlD
Dasatinib—CSK—brain—amyotrophic lateral sclerosis	0.000346	0.00235	CbGeAlD
Dasatinib—Headache—Riluzole—amyotrophic lateral sclerosis	0.000345	0.00178	CcSEcCtD
Dasatinib—HCK—brain—amyotrophic lateral sclerosis	0.000342	0.00232	CbGeAlD
Dasatinib—MAP3K3—nervous system—amyotrophic lateral sclerosis	0.00034	0.00231	CbGeAlD
Dasatinib—MAP4K5—nervous system—amyotrophic lateral sclerosis	0.00034	0.00231	CbGeAlD
Dasatinib—ABL2—brain—amyotrophic lateral sclerosis	0.00034	0.00231	CbGeAlD
Dasatinib—JAK2—central nervous system—amyotrophic lateral sclerosis	0.00034	0.00231	CbGeAlD
Dasatinib—EPHA2—central nervous system—amyotrophic lateral sclerosis	0.000336	0.00228	CbGeAlD
Dasatinib—FYN—central nervous system—amyotrophic lateral sclerosis	0.000335	0.00228	CbGeAlD
Dasatinib—EPHB4—cerebellum—amyotrophic lateral sclerosis	0.000334	0.00227	CbGeAlD
Dasatinib—JAK2—cerebellum—amyotrophic lateral sclerosis	0.000332	0.00226	CbGeAlD
Dasatinib—MAP2K5—spinal cord—amyotrophic lateral sclerosis	0.00033	0.00224	CbGeAlD
Dasatinib—KIT—medulla oblongata—amyotrophic lateral sclerosis	0.000328	0.00223	CbGeAlD
Dasatinib—FYN—cerebellum—amyotrophic lateral sclerosis	0.000327	0.00223	CbGeAlD
Dasatinib—MAP3K3—central nervous system—amyotrophic lateral sclerosis	0.000327	0.00223	CbGeAlD
Dasatinib—MAP4K5—central nervous system—amyotrophic lateral sclerosis	0.000327	0.00223	CbGeAlD
Dasatinib—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000327	0.00169	CcSEcCtD
Dasatinib—EPHB6—nervous system—amyotrophic lateral sclerosis	0.000325	0.00221	CbGeAlD
Dasatinib—CSF1R—spinal cord—amyotrophic lateral sclerosis	0.000322	0.00219	CbGeAlD
Dasatinib—RIPK2—brain—amyotrophic lateral sclerosis	0.000321	0.00219	CbGeAlD
Dasatinib—PDGFRB—medulla oblongata—amyotrophic lateral sclerosis	0.00032	0.00218	CbGeAlD
Dasatinib—MAP4K5—cerebellum—amyotrophic lateral sclerosis	0.00032	0.00218	CbGeAlD
Dasatinib—MAP3K3—cerebellum—amyotrophic lateral sclerosis	0.00032	0.00218	CbGeAlD
Dasatinib—YES1—nervous system—amyotrophic lateral sclerosis	0.000314	0.00214	CbGeAlD
Dasatinib—SIK1—brain—amyotrophic lateral sclerosis	0.000314	0.00213	CbGeAlD
Dasatinib—EPHB6—central nervous system—amyotrophic lateral sclerosis	0.000313	0.00213	CbGeAlD
Dasatinib—EPHA4—brain—amyotrophic lateral sclerosis	0.000311	0.00211	CbGeAlD
Dasatinib—PDGFRA—nervous system—amyotrophic lateral sclerosis	0.000308	0.00209	CbGeAlD
Dasatinib—ERBB3—brain—amyotrophic lateral sclerosis	0.000308	0.00209	CbGeAlD
Dasatinib—EPHB6—cerebellum—amyotrophic lateral sclerosis	0.000306	0.00208	CbGeAlD
Dasatinib—MAP3K2—brain—amyotrophic lateral sclerosis	0.000305	0.00207	CbGeAlD
Dasatinib—YES1—central nervous system—amyotrophic lateral sclerosis	0.000302	0.00206	CbGeAlD
Dasatinib—SRC—nervous system—amyotrophic lateral sclerosis	0.000302	0.00205	CbGeAlD
Dasatinib—PDGFRA—central nervous system—amyotrophic lateral sclerosis	0.000297	0.00202	CbGeAlD
Dasatinib—YES1—cerebellum—amyotrophic lateral sclerosis	0.000296	0.00201	CbGeAlD
Dasatinib—KIT—spinal cord—amyotrophic lateral sclerosis	0.000292	0.00199	CbGeAlD
Dasatinib—SRC—central nervous system—amyotrophic lateral sclerosis	0.000291	0.00198	CbGeAlD
Dasatinib—PDGFRA—cerebellum—amyotrophic lateral sclerosis	0.00029	0.00197	CbGeAlD
Dasatinib—MAPK14—brain—amyotrophic lateral sclerosis	0.000287	0.00195	CbGeAlD
Dasatinib—PDGFRB—spinal cord—amyotrophic lateral sclerosis	0.000286	0.00194	CbGeAlD
Dasatinib—ABL1—medulla oblongata—amyotrophic lateral sclerosis	0.000285	0.00194	CbGeAlD
Dasatinib—FGR—brain—amyotrophic lateral sclerosis	0.000285	0.00194	CbGeAlD
Dasatinib—SRC—cerebellum—amyotrophic lateral sclerosis	0.000284	0.00193	CbGeAlD
Dasatinib—MAP2K5—nervous system—amyotrophic lateral sclerosis	0.000278	0.00189	CbGeAlD
Dasatinib—FMO3—brain—amyotrophic lateral sclerosis	0.000276	0.00187	CbGeAlD
Dasatinib—EPHB4—brain—amyotrophic lateral sclerosis	0.000272	0.00185	CbGeAlD
Dasatinib—CSF1R—nervous system—amyotrophic lateral sclerosis	0.000271	0.00184	CbGeAlD
Dasatinib—JAK2—brain—amyotrophic lateral sclerosis	0.00027	0.00183	CbGeAlD
Dasatinib—MAP2K5—central nervous system—amyotrophic lateral sclerosis	0.000268	0.00182	CbGeAlD
Dasatinib—EPHA2—brain—amyotrophic lateral sclerosis	0.000266	0.00181	CbGeAlD
Dasatinib—FYN—brain—amyotrophic lateral sclerosis	0.000266	0.00181	CbGeAlD
Dasatinib—MAP2K5—cerebellum—amyotrophic lateral sclerosis	0.000262	0.00178	CbGeAlD
Dasatinib—CSF1R—central nervous system—amyotrophic lateral sclerosis	0.000261	0.00178	CbGeAlD
Dasatinib—MAP3K3—brain—amyotrophic lateral sclerosis	0.00026	0.00177	CbGeAlD
Dasatinib—MAP4K5—brain—amyotrophic lateral sclerosis	0.00026	0.00177	CbGeAlD
Dasatinib—CSF1R—cerebellum—amyotrophic lateral sclerosis	0.000255	0.00174	CbGeAlD
Dasatinib—ABL1—spinal cord—amyotrophic lateral sclerosis	0.000254	0.00173	CbGeAlD
Dasatinib—EPHB6—brain—amyotrophic lateral sclerosis	0.000248	0.00169	CbGeAlD
Dasatinib—KIT—nervous system—amyotrophic lateral sclerosis	0.000246	0.00167	CbGeAlD
Dasatinib—PDGFRB—nervous system—amyotrophic lateral sclerosis	0.000241	0.00164	CbGeAlD
Dasatinib—YES1—brain—amyotrophic lateral sclerosis	0.00024	0.00163	CbGeAlD
Dasatinib—KIT—central nervous system—amyotrophic lateral sclerosis	0.000237	0.00161	CbGeAlD
Dasatinib—PDGFRA—brain—amyotrophic lateral sclerosis	0.000236	0.0016	CbGeAlD
Dasatinib—KIT—cerebellum—amyotrophic lateral sclerosis	0.000232	0.00158	CbGeAlD
Dasatinib—PDGFRB—central nervous system—amyotrophic lateral sclerosis	0.000232	0.00157	CbGeAlD
Dasatinib—SRC—brain—amyotrophic lateral sclerosis	0.000231	0.00157	CbGeAlD
Dasatinib—PDGFRB—cerebellum—amyotrophic lateral sclerosis	0.000226	0.00154	CbGeAlD
Dasatinib—ABL1—nervous system—amyotrophic lateral sclerosis	0.000214	0.00146	CbGeAlD
Dasatinib—MAP2K5—brain—amyotrophic lateral sclerosis	0.000212	0.00144	CbGeAlD
Dasatinib—CSF1R—brain—amyotrophic lateral sclerosis	0.000207	0.00141	CbGeAlD
Dasatinib—ABL1—central nervous system—amyotrophic lateral sclerosis	0.000206	0.0014	CbGeAlD
Dasatinib—ABL1—cerebellum—amyotrophic lateral sclerosis	0.000202	0.00137	CbGeAlD
Dasatinib—KIT—brain—amyotrophic lateral sclerosis	0.000188	0.00128	CbGeAlD
Dasatinib—PDGFRB—brain—amyotrophic lateral sclerosis	0.000184	0.00125	CbGeAlD
Dasatinib—CYP1B1—nervous system—amyotrophic lateral sclerosis	0.000182	0.00123	CbGeAlD
Dasatinib—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.00018	0.00122	CbGeAlD
Dasatinib—CYP1B1—central nervous system—amyotrophic lateral sclerosis	0.000175	0.00119	CbGeAlD
Dasatinib—CYP1B1—cerebellum—amyotrophic lateral sclerosis	0.000171	0.00116	CbGeAlD
Dasatinib—ABL1—brain—amyotrophic lateral sclerosis	0.000164	0.00111	CbGeAlD
Dasatinib—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.00016	0.00109	CbGeAlD
Dasatinib—ABCB1—embryo—amyotrophic lateral sclerosis	0.000139	0.000944	CbGeAlD
Dasatinib—CYP1B1—brain—amyotrophic lateral sclerosis	0.000139	0.000944	CbGeAlD
Dasatinib—CYP1A1—nervous system—amyotrophic lateral sclerosis	0.000128	0.000873	CbGeAlD
Dasatinib—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000127	0.000865	CbGeAlD
Dasatinib—CYP1A1—central nervous system—amyotrophic lateral sclerosis	0.000124	0.00084	CbGeAlD
Dasatinib—ABCG2—brain—amyotrophic lateral sclerosis	0.000103	0.000703	CbGeAlD
Dasatinib—CYP1A1—brain—amyotrophic lateral sclerosis	9.81e-05	0.000667	CbGeAlD
Dasatinib—CYP3A4—nervous system—amyotrophic lateral sclerosis	9.42e-05	0.00064	CbGeAlD
Dasatinib—CYP3A4—central nervous system—amyotrophic lateral sclerosis	9.07e-05	0.000616	CbGeAlD
Dasatinib—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	8.87e-05	0.000603	CbGeAlD
Dasatinib—ABCB1—spinal cord—amyotrophic lateral sclerosis	7.91e-05	0.000538	CbGeAlD
Dasatinib—ABCB1—nervous system—amyotrophic lateral sclerosis	6.67e-05	0.000453	CbGeAlD
Dasatinib—ABCB1—central nervous system—amyotrophic lateral sclerosis	6.42e-05	0.000436	CbGeAlD
Dasatinib—ABCB1—cerebellum—amyotrophic lateral sclerosis	6.27e-05	0.000427	CbGeAlD
Dasatinib—ABCB1—brain—amyotrophic lateral sclerosis	5.1e-05	0.000346	CbGeAlD
Dasatinib—RIPK2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.4e-06	4.31e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—ERBB4—amyotrophic lateral sclerosis	8.37e-06	4.3e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	8.37e-06	4.3e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	8.31e-06	4.27e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—MMP9—amyotrophic lateral sclerosis	8.31e-06	4.26e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	8.3e-06	4.26e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—APOE—amyotrophic lateral sclerosis	8.29e-06	4.26e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.25e-06	4.24e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	8.25e-06	4.23e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—C3—amyotrophic lateral sclerosis	8.23e-06	4.22e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CASP9—amyotrophic lateral sclerosis	8.22e-06	4.22e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—MMP9—amyotrophic lateral sclerosis	8.2e-06	4.21e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	8.2e-06	4.21e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	8.12e-06	4.17e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	8.08e-06	4.15e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	8.07e-06	4.14e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—C3—amyotrophic lateral sclerosis	8.05e-06	4.13e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—C3—amyotrophic lateral sclerosis	8.02e-06	4.11e-05	CbGpPWpGaD
Dasatinib—SRC—Axon guidance—VEGFA—amyotrophic lateral sclerosis	8e-06	4.11e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.96e-06	4.08e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—ERBB4—amyotrophic lateral sclerosis	7.94e-06	4.08e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—C3—amyotrophic lateral sclerosis	7.93e-06	4.07e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.9e-06	4.06e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	7.87e-06	4.04e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.85e-06	4.03e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—APOE—amyotrophic lateral sclerosis	7.85e-06	4.03e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	7.83e-06	4.02e-05	CbGpPWpGaD
Dasatinib—YES1—Hemostasis—TP53—amyotrophic lateral sclerosis	7.82e-06	4.01e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.78e-06	4e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.77e-06	3.99e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	7.75e-06	3.98e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.73e-06	3.97e-05	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.72e-06	3.96e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—VEGFA—amyotrophic lateral sclerosis	7.72e-06	3.96e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.69e-06	3.95e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—APOE—amyotrophic lateral sclerosis	7.68e-06	3.94e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—VEGFA—amyotrophic lateral sclerosis	7.68e-06	3.94e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.67e-06	3.94e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	7.67e-06	3.94e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—C3—amyotrophic lateral sclerosis	7.63e-06	3.92e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—VEGFA—amyotrophic lateral sclerosis	7.6e-06	3.9e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CASP9—amyotrophic lateral sclerosis	7.59e-06	3.89e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.57e-06	3.88e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—C3—amyotrophic lateral sclerosis	7.54e-06	3.87e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.51e-06	3.85e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7.48e-06	3.84e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CD40LG—amyotrophic lateral sclerosis	7.47e-06	3.83e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	7.46e-06	3.83e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	7.46e-06	3.83e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	7.41e-06	3.8e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.39e-06	3.79e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	7.36e-06	3.78e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—ERBB4—amyotrophic lateral sclerosis	7.33e-06	3.76e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7.32e-06	3.76e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—VEGFA—amyotrophic lateral sclerosis	7.32e-06	3.76e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.29e-06	3.74e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	7.26e-06	3.73e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—PTGS2—amyotrophic lateral sclerosis	7.25e-06	3.72e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	7.22e-06	3.71e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—VEGFA—amyotrophic lateral sclerosis	7.22e-06	3.71e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7.21e-06	3.7e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.19e-06	3.69e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.16e-06	3.67e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.1e-06	3.65e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—APOE—amyotrophic lateral sclerosis	7.07e-06	3.63e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.06e-06	3.62e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—ERBB4—amyotrophic lateral sclerosis	7.03e-06	3.61e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	7e-06	3.59e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.98e-06	3.58e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.98e-06	3.58e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.94e-06	3.56e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.94e-06	3.56e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.85e-06	3.52e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—APOE—amyotrophic lateral sclerosis	6.82e-06	3.5e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.76e-06	3.47e-05	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.73e-06	3.45e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	6.72e-06	3.45e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.69e-06	3.43e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.68e-06	3.43e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD40LG—amyotrophic lateral sclerosis	6.61e-06	3.39e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—C3—amyotrophic lateral sclerosis	6.6e-06	3.39e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	6.57e-06	3.37e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.5e-06	3.34e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—ERBB4—amyotrophic lateral sclerosis	6.49e-06	3.33e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—APOE—amyotrophic lateral sclerosis	6.48e-06	3.33e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	6.45e-06	3.31e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6.4e-06	3.29e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—MMP9—amyotrophic lateral sclerosis	6.36e-06	3.26e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.35e-06	3.26e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—VEGFA—amyotrophic lateral sclerosis	6.33e-06	3.25e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.3e-06	3.23e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.27e-06	3.22e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6.27e-06	3.22e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.24e-06	3.2e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6.17e-06	3.17e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.15e-06	3.16e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	6.12e-06	3.14e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.12e-06	3.14e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.09e-06	3.12e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.07e-06	3.12e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.02e-06	3.09e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6e-06	3.08e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	5.95e-06	3.06e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	5.95e-06	3.05e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.94e-06	3.05e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.9e-06	3.03e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.89e-06	3.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.86e-06	3.01e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—C3—amyotrophic lateral sclerosis	5.84e-06	3e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—TP53—amyotrophic lateral sclerosis	5.83e-06	2.99e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.81e-06	2.98e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—TP53—amyotrophic lateral sclerosis	5.8e-06	2.98e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.8e-06	2.98e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—TP53—amyotrophic lateral sclerosis	5.74e-06	2.95e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	5.71e-06	2.93e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—PTGS2—amyotrophic lateral sclerosis	5.68e-06	2.92e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—APOE—amyotrophic lateral sclerosis	5.67e-06	2.91e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—VEGFA—amyotrophic lateral sclerosis	5.6e-06	2.87e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.59e-06	2.87e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.59e-06	2.87e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	5.58e-06	2.86e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—TP53—amyotrophic lateral sclerosis	5.53e-06	2.84e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.51e-06	2.83e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.5e-06	2.82e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	5.46e-06	2.8e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—TP53—amyotrophic lateral sclerosis	5.46e-06	2.8e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.42e-06	2.78e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—PTGS2—amyotrophic lateral sclerosis	5.38e-06	2.76e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.37e-06	2.76e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.34e-06	2.74e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.32e-06	2.73e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	5.31e-06	2.73e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.21e-06	2.67e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.14e-06	2.64e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.13e-06	2.63e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—APOE—amyotrophic lateral sclerosis	5.06e-06	2.6e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.05e-06	2.59e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—APOE—amyotrophic lateral sclerosis	5.02e-06	2.58e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	4.98e-06	2.56e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.95e-06	2.54e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.94e-06	2.53e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	4.89e-06	2.51e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.89e-06	2.51e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.87e-06	2.5e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.85e-06	2.49e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PTGS2—amyotrophic lateral sclerosis	4.84e-06	2.49e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.83e-06	2.48e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.8e-06	2.46e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.79e-06	2.46e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—amyotrophic lateral sclerosis	4.78e-06	2.45e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.77e-06	2.45e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.74e-06	2.43e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.71e-06	2.42e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—PTGS2—amyotrophic lateral sclerosis	4.67e-06	2.4e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.62e-06	2.37e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	4.6e-06	2.36e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.6e-06	2.36e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	4.59e-06	2.36e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.59e-06	2.36e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.55e-06	2.33e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.54e-06	2.33e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.54e-06	2.33e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.53e-06	2.33e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.46e-06	2.29e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.45e-06	2.28e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—PTGS2—amyotrophic lateral sclerosis	4.44e-06	2.28e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.36e-06	2.24e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.28e-06	2.19e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.27e-06	2.19e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—amyotrophic lateral sclerosis	4.23e-06	2.17e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.15e-06	2.13e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.13e-06	2.12e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.12e-06	2.12e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.09e-06	2.1e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.01e-06	2.06e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.01e-06	2.06e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4e-06	2.05e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.97e-06	2.04e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.94e-06	2.02e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.91e-06	2.01e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—PTGS2—amyotrophic lateral sclerosis	3.89e-06	2e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.8e-06	1.95e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.79e-06	1.94e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.78e-06	1.94e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	3.77e-06	1.94e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.75e-06	1.92e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.69e-06	1.9e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.52e-06	1.81e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.51e-06	1.8e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.5e-06	1.79e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.49e-06	1.79e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.47e-06	1.78e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—PTGS2—amyotrophic lateral sclerosis	3.44e-06	1.77e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.43e-06	1.76e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.3e-06	1.7e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	3.3e-06	1.69e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.29e-06	1.69e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.28e-06	1.69e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.15e-06	1.62e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.15e-06	1.62e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.13e-06	1.61e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.13e-06	1.61e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—APOE—amyotrophic lateral sclerosis	3.12e-06	1.6e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.08e-06	1.58e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.06e-06	1.57e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.04e-06	1.56e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.02e-06	1.55e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.02e-06	1.55e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.98e-06	1.53e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.97e-06	1.52e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.92e-06	1.5e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.91e-06	1.5e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.91e-06	1.49e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.89e-06	1.48e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.87e-06	1.47e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.76e-06	1.42e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.73e-06	1.4e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.67e-06	1.37e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.65e-06	1.36e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.63e-06	1.35e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.62e-06	1.34e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.58e-06	1.32e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.53e-06	1.3e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	2.49e-06	1.28e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.48e-06	1.27e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.45e-06	1.26e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.41e-06	1.24e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.39e-06	1.23e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.37e-06	1.22e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.26e-06	1.16e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.24e-06	1.15e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.24e-06	1.15e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.14e-06	1.1e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.14e-06	1.1e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.11e-06	1.09e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.03e-06	1.04e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.02e-06	1.04e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	1.99e-06	1.02e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.98e-06	1.01e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.95e-06	9.99e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.9e-06	9.74e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.87e-06	9.62e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.86e-06	9.57e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.85e-06	9.5e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.71e-06	8.75e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.62e-06	8.32e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.53e-06	7.87e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.43e-06	7.36e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.36e-06	6.99e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.05e-06	5.39e-06	CbGpPWpGaD
